VivoSeq
Cardiovascular

Essential Hypertension

215

Pipeline Programs↗

15

Active Trials↗

60

Companies Involved↗

Essential Hypertension is a highly competitive landscape with 215 programs across 60 companies. The most active players are PhaseBio Pharmaceuticals Inc., Qilu Pharmaceutical Co., Ltd., Exela Pharma Sciences, LLC.. 39 therapies are approved with 103 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

22/100

Mech. Concentration

24/100

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

PhaseBio Pharmaceuticals Inc.

2 programs

Phase 1Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Phase 1E

Exela Pharma Sciences, LLC.

1 program

Phase 1Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 1S

Shin Poong Pharmaceutical Co. Ltd.

8 programs

Phase 2Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical16

Colchicine

Alnylam Pharmaceuticals

Iloprost

BTG International Inc.

Micardis

Boehringer Ingelheim

Lisinopril

Twinpig Biolab, Inc.

Thiazide and Beta Blocker

University of Cambridge

Phase 111

Angiotensin-(1-7)

University of Arizona

Phenylephrine

Exela Pharma Sciences, LLC.

Trimethaphan

Vanderbilt University

Naproxcinod

NicOx

KK3910

Kyowa Kirin Co., Ltd.

Phase 246

Candesartan

AstraZeneca

Melatonin

Neurim Pharmaceuticals Ltd.

Nebivolol

Vitae Pharmaceuticals Inc., an Allergan affiliate

LCZ696

Novartis

Allopurinol

Alnylam Pharmaceuticals

Phase 3103

Losartan Potassium

Merck & Co.

Bexagliflozin

Theracosbio

Chlorthalidone

Alnylam Pharmaceuticals

Fimasartan

Boryung Pharmaceutical Co., Ltd

Olmesartan

Novartis

Approved39

Aliskiren

Tibotec Pharmaceuticals, Ireland

Hydrochlorothiazide

AbbVie

Captopril

Standard Chem. & Pharm. Co., Ltd.

Aspirin

Bayer

Rifampin

Sanofi

Analysis

Trial Status

206

clinical trials

Completed163 · 79%
Unknown status16 · 8%
Terminated7 · 3%
Not yet recruiting6 · 3%
Withdrawn5 · 2%
Recruiting5 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

206 trials

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Recruiting·AAJU Pharm Co., Ltd.·Phase 3·NCT06416865·190 enrolled
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
Recruiting·TTHPharm Corp.·Phase 3·NCT06647745·221 enrolled
To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
Recruiting·SSuzhou Alphamab Co., Ltd.·Phase 1·NCT07191899·60 enrolled
Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
Recruiting·GGenuine Research Center, Egypt·Phase 4·NCT05880056·406 enrolled
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Recruiting·SShin Poong Pharmaceutical Co. Ltd.·Phase 2·NCT06826872·252 enrolled
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
Active, not recruiting·YYuhan Corporation·Phase 4·NCT06041529·198 enrolled
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
Active, not recruiting·YYuhan Corporation·N/A·NCT06282549·1,219 enrolled
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Not yet recruiting·WWuhan Createrna Science and Technology Co., Ltd·Phase 3·NCT06716970·810 enrolled
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
Not yet recruiting·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·Phase 2·NCT07373613·330 enrolled
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
Not yet recruiting·EEurofarma Laboratorios S.A.·Phase 3·NCT06608472·292 enrolled
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 4·NCT06501651·297 enrolled
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension
Not yet recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 1·NCT07152444·78 enrolled
A Multicenter, Prospective Observational Study to Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe' in Patients With Essential Hypertension and Primary Hypercholesterolemia.
Not yet recruiting·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·N/A·NCT07685054·12,700 enrolled
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Enrolling by invitation·SShin Poong Pharmaceutical Co. Ltd.·Phase 2·NCT07064525·252 enrolled
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Enrolling by invitation·HHyundai Pharm·Phase 3·NCT06646354·125 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)